Unique five-year agreement will help Philadelphia-based health leader integrate and standardize innovative cardiovascular care, helping to deliver on the quadruple aim “Through this innovative ...

Findings that evolocumab significantly reduced the risk of major adverse CV events in adults at high CV risk without prior heart attack or stroke vs placebo. Topline data were announced from a phase 3 ...

The American Heart Association and the American College of Cardiology, along with two other leading medical organizations ...

Just over a year since AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular (CV) death and heart failure–related hospitalizations for ...

Integrating physicians with a hospital is becoming increasingly important as healthcare delivery shifts away from fee-for-service to those rewarding more coordinated care. One way to integrate ...